About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
MBRX - Moleculin Biotech| Previous Close | $0.81 | Open | |
| Volume | Market Cap | 48.96M | |
| Yield | Last Dividend |
| Moleculin Announces COVID-19 In Vivo Tes... | 09/14/20 |
| HOUSTON, Sept. 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin Announces Successful Completio... | 09/09/20 |
| HOUSTON, Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company... | |
| Moleculin Biotech???s Antimetabolites CO... | 07/21/20 |
| No summary available. | |
| Moleculin Pops 33% On Anti-Viral Activit... | 07/21/20 |
| Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug c... | |
| Thinking about buying stock in Moleculin... | 07/15/20 |
| NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBRX, VBIV, RIGL, DAL, and VSLR. To see how InvestorsO... | |
| Nasdaq Halts Moleculin Biotech Inc. | 05/18/20 |
| NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market?? (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc???... | |
| Moleculin Biotech shares remain halted o... | 05/18/20 |
| Moleculin Biotech Inc. undefined said Monday its shares remain halted on Nasdaq with the exchange seeking additional information from the company. Sha... | |
| Moleculin to Speak on COVID-19 Panel at ... | 04/29/20 |
| HOUSTON, April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin Approved to Accelerate Europea... | 04/28/20 |
| HOUSTON, April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin Biotech, Inc. (MBRX) Flat As M... | 04/27/20 |
| Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session. | |
| Is Moleculin Biotech (MBRX) Stock Outpac... | 04/27/20 |
| Is (MBRX) Outperforming Other Medical Stocks This Year? | |
| Moleculin Announces Agreement with ImQue... | 04/20/20 |
| HOUSTON, April 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin to Host Investor Conference Ca... | 04/16/20 |
| HOUSTON, April 16, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin Biotech to host investor call ... | 04/16/20 |
| WPD Pharmaceuticals' (OTCPK:WCOTF) license partner, Moleculin Biotech will host a web-based investor conference call, today at 4:30 pm ET to explain t... | |
| Moleculin Announces Leading Virologist J... | 04/15/20 |
| HOUSTON, April 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... | |
| Moleculin (MBRX) Looks Good: Stock Adds ... | 04/14/20 |
| Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. | |
| Moleculin Announces Investor Conference ... | 04/14/20 |
| Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candida... | |
| Is Moleculin Biotech (MBRX) Outperformin... | 04/09/20 |
| Is (MBRX) Outperforming Other Medical Stocks This Year? | |
| Why Moleculin Biotech???s Coronavirus Tr... | 04/08/20 |
| No summary available. | |
| Thinking about buying stock in Camber En... | 04/08/20 |
| NEW YORK, April 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, CY, DAL, MBRX, and TOPS. To see how InvestorsObse... | |
| Moleculin Biotech Doubles In Pre-Market ... | 04/08/20 |
| Moleculin Biotech (MBRX) today announced that independent research found 2-deoxy-D-glucose (???2-DG???) to reduce the virus that causes COVID-19 by 10... | |
| Moleculin Signs Agreement with UTMB to T... | 03/17/20 |
| HOUSTON , March 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX ) ("Moleculin" or the "Company"), a clinical stage pharmaceutical comp... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| Moleculin Announces Positive Independent... | 02/20/20 |
| HOUSTON, Feb. 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company... | |
| The Daily Biotech Pulse: LogicBio Slappe... | 02/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) ... | |
| Moleculin Announces $6.0 Million Registe... | 02/06/20 |
| HOUSTON, Feb. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ... | |
| Moleculin to Seek Accelerated FDA Approv... | 02/05/20 |
| HOUSTON, Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ... | |
| Moleculin Announces Successful Completio... | 02/03/20 |
| HOUSTON, Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ... | |
| Moleculin Announces New Data Shows Rever... | 12/19/19 |
| HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company... | |
| Moleculin Announces Additional Positive ... | 12/04/19 |
| /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
